Ligand Pharmaceuticals IncorporatedSEC Filings
|
|
All SEC filings by Ligand Pharmaceuticals Incorporated (LGND) — annual and quarterly reports, current reports, registrations, proxies and ownership forms, updated in real time.
Financials
| 10-Q | Quarterly report | View Diff | Aug 7, 2026 | |
| 10-Q | Quarterly report | View Diff | May 8, 2026 | |
| ARS | Annual report to shareholders | Apr 21, 2026 | ||
| 10-K | Annual report | View Diff | Feb 27, 2026 | |
| 10-Q | Quarterly report | View Diff | Nov 7, 2025 | |
| 10-Q | Quarterly report | View Diff | Aug 8, 2025 | |
| 10-Q | Quarterly report | View Diff | May 9, 2025 | |
| ARS | Annual report to shareholders | Apr 22, 2025 | ||
| 10-K | Annual report | View Diff | Feb 28, 2025 | |
| 10-Q | Quarterly report | View Diff | Nov 8, 2024 |
Events
| 8-K/A | Current report | Sep 2, 2026 | ||
| 8-K | Ligand Reports Second Quarter 2026 Financial Results | Aug 6, 2026 | ||
| 8-K | Ligand Completes Acquisition of Xoma Royalty, Creating a Portfolio of More Than 200 Biopharmaceutical Royalty Assets | Jul 14, 2026 | ||
| 8-K | Current report | Jun 25, 2026 | ||
| 8-K | Current report | Jun 22, 2026 | ||
| 8-K | Current report | Jun 9, 2026 | ||
| 8-K | Entry Into a Material Definitive Agreement | May 18, 2026 | ||
| 8-K | Ligand Reports First Quarter 2026 Financial Results | May 7, 2026 | ||
| 8-K | Termination of a Material Definitive Agreement | Apr 30, 2026 | ||
| 8-K | Ligand to Acquire Xoma Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator | Apr 27, 2026 |
Registrations and Prospectuses
| S-8 | Registration of securities for employees | Jul 22, 2026 | ||
| S-3ASR | Automatic shelf registration | Feb 27, 2026 | ||
| S-8 | Registration of securities for employees | Jul 9, 2024 | ||
| S-8 | Registration of securities for employees | Mar 1, 2024 | ||
| 425 | Business combination disclosure | Oct 3, 2022 | ||
| S-3ASR | Automatic shelf registration | Sep 30, 2022 | ||
| 425 | Business combination disclosure | Aug 24, 2022 | ||
| S-8 | Registration of securities for employees | Aug 10, 2022 | ||
| 425 | Business combination disclosure | Jun 21, 2022 | ||
| S-8 | Registration of securities for employees | Jun 13, 2022 |
Proxies
| DEFA14A | Additional proxy soliciting materials | May 18, 2026 | ||
| DEFA14A | Additional proxy soliciting materials | Apr 27, 2026 | ||
| DEFA14A | Additional proxy soliciting materials | Apr 27, 2026 | ||
| DEFA14A | Additional proxy soliciting materials | Apr 21, 2026 | ||
| DEF 14A | Definitive proxy | View Diff | Apr 21, 2026 | |
| DEFA14A | Additional proxy soliciting materials | Apr 22, 2025 | ||
| DEF 14A | Definitive proxy | View Diff | Apr 22, 2025 | |
| DEFA14A | Additional proxy soliciting materials | Jun 3, 2024 | ||
| DEFA14A | Additional proxy soliciting materials | May 9, 2024 | ||
| DEFA14A | Additional proxy soliciting materials | Apr 24, 2024 |
Other
| CT ORDER | Confidential treatment order | Apr 26, 2023 | ||
| UPLOAD | Letter from SEC | Jan 13, 2021 | ||
| CORRESP | Correspondence with SEC | Jan 6, 2021 | ||
| UPLOAD | Letter from SEC | Dec 23, 2020 | ||
| CORRESP | Correspondence with SEC | Sep 16, 2020 | ||
| CT ORDER | Confidential treatment order | Jun 15, 2020 | ||
| CT ORDER | Confidential treatment order | Aug 24, 2018 | ||
| CT ORDER | Confidential treatment order | May 22, 2018 | ||
| CT ORDER | Confidential treatment order | Apr 3, 2018 | ||
| UPLOAD | Letter from SEC | Feb 7, 2018 |
Ownership
| 144 | Notice of proposed sale of securities | Sep 3, 2026 | ||
| 4 | Espinoza Octavio | Aug 14, 2026 | ||
| 4 | Haas Jason | Aug 14, 2026 | ||
| SC 13G | Beneficial ownership report | Aug 13, 2026 | ||
| 144 | Notice of proposed sale of securities | Aug 12, 2026 | ||
| 144 | Notice of proposed sale of securities | Aug 12, 2026 | ||
| 4 | Reardon Andrew | Aug 4, 2026 | ||
| 4 | Reardon Andrew | Jul 6, 2026 | ||
| 4 | Espinoza Octavio | Jul 6, 2026 | ||
| 4 | Davis Todd C | Jul 6, 2026 |